Abstract
Axl receptor tyrosine kinase (RTK) and its ligand, growth arrest-specific protein 6 (Gas6), are involved in several biological functions and participate in the development and progression of a range of malignancies and autoimmune disorders. In this review, we present this molecular system from a drug discovery perspective, highlighting its therapeutic implications and challenges that need to be addressed. We provide an update on Axl/Gas6 axis biology, exploring its role in fields ranging from angiogenesis, cancer development and metastasis, immune response and inflammation to viral infection. Finally, we summarize the molecules that have been developed to date to target the Axl/Gas6 molecular system for therapeutic and diagnostic applications.
Copyright © 2020 Elsevier Ltd. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Animals
-
Antineoplastic Agents / therapeutic use
-
Autoimmune Diseases / immunology
-
Axl Receptor Tyrosine Kinase
-
Cell- and Tissue-Based Therapy
-
Humans
-
Intercellular Signaling Peptides and Proteins / immunology
-
Intercellular Signaling Peptides and Proteins / metabolism*
-
Molecular Targeted Therapy
-
Neoplasms / metabolism
-
Neoplasms / pathology
-
Neoplasms / therapy
-
Neovascularization, Pathologic / metabolism
-
Neovascularization, Pathologic / therapy
-
Protein Kinase Inhibitors / therapeutic use
-
Proto-Oncogene Proteins / antagonists & inhibitors
-
Proto-Oncogene Proteins / immunology
-
Proto-Oncogene Proteins / metabolism*
-
Receptor Protein-Tyrosine Kinases / antagonists & inhibitors
-
Receptor Protein-Tyrosine Kinases / immunology
-
Receptor Protein-Tyrosine Kinases / metabolism*
-
Virus Diseases / metabolism
Substances
-
Antineoplastic Agents
-
Intercellular Signaling Peptides and Proteins
-
Protein Kinase Inhibitors
-
Proto-Oncogene Proteins
-
growth arrest-specific protein 6
-
Receptor Protein-Tyrosine Kinases
-
Axl Receptor Tyrosine Kinase
-
AXL protein, human